Semanteon Capital Management LP Takes $520,000 Position in Henry Schein, Inc. $HSIC

Semanteon Capital Management LP acquired a new position in Henry Schein, Inc. (NASDAQ:HSIC) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 7,829 shares of the company’s stock, valued at approximately $520,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HSIC. CYBER HORNET ETFs LLC bought a new position in shares of Henry Schein in the 2nd quarter valued at about $25,000. MUFG Securities EMEA plc bought a new position in Henry Schein in the second quarter valued at approximately $27,000. ANTIPODES PARTNERS Ltd acquired a new stake in Henry Schein during the 2nd quarter worth $43,000. Sentry Investment Management LLC raised its position in shares of Henry Schein by 132.1% during the 3rd quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock valued at $59,000 after acquiring an additional 515 shares during the last quarter. Finally, Evelyn Partners Investment Management Services Ltd bought a new stake in shares of Henry Schein during the 2nd quarter valued at $62,000. 96.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HSIC. Wells Fargo & Company lifted their price objective on Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Barrington Research set a $79.00 price target on Henry Schein and gave the company an “outperform” rating in a research note on Wednesday, November 5th. JPMorgan Chase & Co. lifted their price objective on shares of Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Mizuho set a $81.00 target price on shares of Henry Schein and gave the company a “neutral” rating in a research note on Tuesday, January 20th. Finally, Morgan Stanley increased their target price on shares of Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a report on Wednesday, November 5th. Five research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $76.42.

Henry Schein Stock Up 3.6%

Henry Schein stock opened at $79.57 on Friday. The stock has a market capitalization of $9.37 billion, a PE ratio of 25.18, a price-to-earnings-growth ratio of 2.37 and a beta of 0.88. Henry Schein, Inc. has a twelve month low of $60.56 and a twelve month high of $82.80. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54. The company has a 50 day moving average of $77.37 and a 200-day moving average of $71.64.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.